Skip to main content
SpringerLink
Log in

Neuroendocrine Tumors of the Urinary Bladder

  • Chapter
  • First Online:
Urinary Bladder Pathology

  • 774 Accesses

Abstract

Primary neuroendocrine tumors of the urinary bladder are relatively rare and are comprised of a heterogeneous group of neoplasms. These include well-differentiated neuroendocrine tumors (WDNETs) or carcinoid tumors; poorly differentiated neuroendocrine carcinomas (NEC), including small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC); and paraganglioma. These tumors are believed to arise from native neuroendocrine cells in the urothelial lining in the case of WDNETs, transdifferentiation of urothelial carcinoma cells in the case of poorly differentiated NECs, and chromaffin cells in autonomic ganglia in the case of paraganglioma. These tumors have different treatment protocols and clinical outcomes than conventional urothelial carcinoma, with SCNEC and LCNEC having a more aggressive course and worse outcomes and WDNET and paraganglioma having a more indolent course and better outcomes. Therefore, the proper recognition of these tumors is important. The epidemiological data; clinical information; histopathologic, immunohistochemical, and molecular features; prognostic factors; and therapeutic approaches of these entities are discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. https://doi.org/10.1016/j.eururo.2016.02.029.

    Article  PubMed  Google Scholar 

  2. Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics. Endocr Pathol. 2016;27(3):188–99. https://doi.org/10.1007/s12022-016-9444-5.

    Article  PubMed  Google Scholar 

  3. Purnell S, Sidana A, Maruf M, Grant C, Agarwal PK. Genitourinary paraganglioma: demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000–2012). Urol Oncol. 2017;35(7):457.e9–457.e14. https://doi.org/10.1016/j.urolonc.2017.02.006.

    Article  Google Scholar 

  4. Posfai B, Kuthi L, Varga L, et al. The colorful palette of neuroendocrine neoplasms in the genitourinary tract. Anticancer Res. 2018;38(6):3243–54. https://doi.org/10.21873/anticancers.12589.

    Article  CAS  PubMed  Google Scholar 

  5. Chen Y, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol. 2011;35(3):442–6. https://doi.org/10.1097/PAS.0b013e318208f96a.

    Article  CAS  PubMed  Google Scholar 

  6. Mascolo M, Altieri V, Mignogna C, Napodano G, De Rosa G, Insabato L. Calcitonin-producing well-differentiated neuroendocrine carcinoma (carcinoid tumor) of the urinary bladder: case report. BMC Cancer. 2005;5:88. https://doi.org/10.1186/1471-2407-5-88.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hemal AK, Singh I, Pawar R, Kumar M, Taneja P. Primary malignant bladder carcinoid— a diagnostic and management dilemma. Urology. 2000;55(6):949. https://doi.org/10.1016/S0090-4295(00)00470-2.

    Article  CAS  PubMed  Google Scholar 

  8. Sugihara A, Kajio K, Yoshimoto T, et al. Primary carcinoid tumor of the urinary bladder. Int Urol Nephrol. 2002;33(1):53–7. https://doi.org/10.1023/a:1014400818905.

    Article  PubMed  Google Scholar 

  9. Baydar DE, Tasar C. Carcinoid tumor in the urinary bladder: unreported features. Am J Surg Pathol. 2011;35(11):1754–7. https://doi.org/10.1097/PAS.0b013e31823455eb.

    Article  PubMed  Google Scholar 

  10. Zozumi M, Nakai M, Matsuda I, et al. Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules. Pathol Res Pract. 2012;208(2):109–12. https://doi.org/10.1016/j.prp.2011.10.008.

    Article  CAS  PubMed  Google Scholar 

  11. Erdem GU, Özdemir NY, Demirci NS, Şahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin. 2016;32(6):1013–21. https://doi.org/10.1185/03007995.2016.1155982.

    Article  PubMed  Google Scholar 

  12. Sroussi M, Elaidi R, Fléchon A, et al. Neuroendocrine carcinoma of the urinary bladder: a large, Retrospective Study From the French Genito-Urinary Tumor Group. Clin Genitourin Cancer. Published online December 5, 2019. https://doi.org/10.1016/j.clgc.2019.11.014.

  13. Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1–11. https://doi.org/10.1159/000224860.

    Article  PubMed  Google Scholar 

  14. Schneider NI, Zigeuner R, Langner C. Small cell carcinoma of the urinary bladder: a rare tumor with propensity for hepatic involvement. Am J Med Sci. 2013;345(2):155–7. https://doi.org/10.1097/MAJ.0b013e3182648759.

    Article  PubMed  Google Scholar 

  15. Perán Teruel M, Giménez Bachs JM, Martínez Ruiz J, et al. Neuroendocrine carcinoma of the urinary bladder. 15-year retrospective analysis. Arch Esp Urol. 2012;65(2):237–43.

    PubMed  Google Scholar 

  16. Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 81 cases. Hum Pathol. 2018;79:57–65. https://doi.org/10.1016/j.humpath.2018.05.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cheng L, Pan C-X, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957–62. https://doi.org/10.1002/cncr.20456.

    Article  PubMed  Google Scholar 

  18. Choong NWW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172–8. https://doi.org/10.1002/cncr.20903.

    Article  PubMed  Google Scholar 

  19. Fine SW. Neuroendocrine lesions of the genitourinary tract. Adv Anat Pathol. 2007;14(4):286–96. https://doi.org/10.1097/PAP.0b013e3180ca8a89.

    Article  PubMed  Google Scholar 

  20. Smith J, Reidy-Lagunes D. The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Semin Oncol. 2013;40(1):100–8. https://doi.org/10.1053/j.seminoncol.2012.11.011.

    Article  PubMed  Google Scholar 

  21. Thompson S, Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Fernandez-Castro G, Jorda M. Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach. Appl Immunohistochem Mol Morphol. 2011;19(5):395–9. https://doi.org/10.1097/PAI.0b013e31820eca9a.

    Article  CAS  PubMed  Google Scholar 

  22. Pant-Purohit M, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Small cell carcinoma of the urinary bladder. Histol Histopathol. 2010;25(2):217–21. https://doi.org/10.14670/HH-25.217.

    Article  PubMed  Google Scholar 

  23. Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123(22):4346–55. https://doi.org/10.1002/cncr.30907.

    Article  CAS  PubMed  Google Scholar 

  24. Niu Q, Lu Y, Xu S, et al. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479–89. https://doi.org/10.2147/CMAR.S175286.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kanagarajah P, Ayyathurai R, Saleem U, Manoharan M. Small cell carcinoma arising from the bulbar urethra: a case report and literature review. Urol Int. 2012;88(4):477–9. https://doi.org/10.1159/000332154.

    Article  PubMed  Google Scholar 

  26. Acosta AM, Kajdacsy-Balla A. Primary neuroendocrine tumors of the ureter: a short review. Arch Pathol Lab Med. 2016;140(7):714–7. https://doi.org/10.5858/arpa.2015-0106-RS.

    Article  PubMed  Google Scholar 

  27. Kim TS, Seong DH, Ro JY. Small cell carcinoma of the ureter with squamous cell and transitional cell carcinomatous components associated with ureteral stone. J Korean Med Sci. 2001;16(6):796–800. https://doi.org/10.3346/jkms.2001.16.6.796.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Pompas-Veganzones N, Gonzalez-Peramato P, Sanchez-Carbayo M. The neuroendocrine component in bladder tumors. Curr Med Chem. 2014;21(9):1117–28.

    Article  CAS  Google Scholar 

  29. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer registry. J Urol. 2010;183(3):915–20. https://doi.org/10.1016/j.juro.2009.11.018.

    Article  PubMed  Google Scholar 

  30. Grignon DJ, Ro JY, Ayala AG, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992;69(2):527–36.

    Article  CAS  Google Scholar 

  31. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46(1):57–63. https://doi.org/10.1111/j.1365-2559.2004.01980.x.

    Article  CAS  PubMed  Google Scholar 

  32. Terracciano L, Richter J, Tornillo L, et al. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol. 1999;189(2):230–5. https://doi.org/10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8.

    Article  CAS  PubMed  Google Scholar 

  33. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533–9.

    Article  CAS  Google Scholar 

  34. Chang MT, Penson A, Desai NB, et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965–73. https://doi.org/10.1158/1078-0432.CCR-17-2655.

    Article  CAS  PubMed  Google Scholar 

  35. Wang Y, Li Q, Wang J, et al. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up. Med Oncol. 2019;36(12):98. https://doi.org/10.1007/s12032-019-1321-x.

    Article  PubMed  Google Scholar 

  36. Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014;7(1):47. https://doi.org/10.1186/s13045-014-0047-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sjödahl G. Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel. Methods Mol Biol. 1655;2018:53–64. https://doi.org/10.1007/978-1-4939-7234-0_5.

    Article  CAS  Google Scholar 

  38. Kim IE, Amin A, Wang LJ, Cheng L, Perrino CM. Insulinoma-associated protein 1 (INSM1) expression in small cell neuroendocrine carcinoma of the urinary tract. Appl Immunohistochem Mol Morphol. Published online December 23, 2019. https://doi.org/10.1097/PAI.0000000000000824.

  39. Lan MS, Breslin MB. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 2009;23:2024–33.

    Article  CAS  Google Scholar 

  40. Soriano P, Navarro S, Gil M, Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch. 2004;445(3):292–7. https://doi.org/10.1007/s00428-004-1041-1.

    Article  CAS  PubMed  Google Scholar 

  41. Blomjous CE, Vos W, Schipper NW, De Voogt HJ, Baak JP, Meijer CJ. Morphometric and flow cytometric analysis of small cell undifferentiated carcinoma of the bladder. J Clin Pathol. 1989;42(10):1032–9. https://doi.org/10.1136/jcp.42.10.1032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64(6):1347–57. https://doi.org/10.1002/1097-0142(19890915)64:6<1347::aid-cncr2820640629>3.0.co;2-q.

    Article  CAS  PubMed  Google Scholar 

  43. Bezerra SM, Lotan TL, Faraj SF, et al. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. Hum Pathol. 2014;45(8):1682–7. https://doi.org/10.1016/j.humpath.2014.04.011.

    Article  CAS  PubMed  Google Scholar 

  44. Li W, Liang Y, Deavers MT, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014;142(6):864–71. https://doi.org/10.1309/AJCP1J0JPJBPSUXF.

    Article  PubMed  Google Scholar 

  45. Paner GP, Lopez-Beltran A, Sirohi D, Amin MB. Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin. Adv Anat Pathol. 2016;23(2):71–83. https://doi.org/10.1097/PAP.0000000000000110.

    Article  CAS  PubMed  Google Scholar 

  46. Fernández-Aceñero MJ, Córdova S, Manzarbeitia F, Medina C. Immunohistochemical profile of urothelial and small cell carcinomas of the bladder. Pathol Oncol Res. 2011;17(3):519–23. https://doi.org/10.1007/s12253-010-9341-z.

    Article  CAS  PubMed  Google Scholar 

  47. Iczkowski KA, Shanks JH, Bostwick DG. Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. Histopathology. 1998;32(4):322–7. https://doi.org/10.1046/j.1365-2559.1998.00398.x.

    Article  CAS  PubMed  Google Scholar 

  48. Neşe N, Kumbaraci BS, Baydar DE, et al. Small cell carcinomas of the bladder highly express somatostatin receptor type 2A: impact on prognosis and treatment—a multicenter study of Urooncology society, Turkey. Appl Immunohistochem Mol Morphol. 2016;24(4):253–60. https://doi.org/10.1097/PAI.0000000000000188.

    Article  CAS  PubMed  Google Scholar 

  49. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097–105. https://doi.org/10.1097/PAS.0b013e3181e6cbf3.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch. 2013;463(6):803–9. https://doi.org/10.1007/s00428-013-1495-0.

    Article  CAS  PubMed  Google Scholar 

  51. Akdeniz E, Bakirtas M, Bolat MS, Akdeniz S, Özer I. Pure large cell neuroendocrine carcinoma of the bladder without urological symptoms. Pan Afr Med J. 2018;30:134. https://doi.org/10.11604/pamj.2018.30.134.13437.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Martín IJP, Vilar DG, Aguado JM, et al. Large cell neuroendocrine carcinoma of the urinary bladder. Bibliographic review. Arch Esp Urol. 2011;64(2):105–13.

    PubMed  Google Scholar 

  53. Watson GA, Ahmed Y, Picardo S, et al. Unusual Sites of High-Grade Neuroendocrine Carcinomas: A Case Series and Review of the Literature. Am J Case Rep. 2018;19:710–23. https://doi.org/10.12659/AJCR.908953.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Sari A, Ermete M, Sadullahoğlu C, Bal K, Bolükbaşi A. Large cell neuroendocrine carcinoma of urinary bladder; case presentation. Turk Patoloji Derg. 2013;29(2):138–42. https://doi.org/10.5146/tjpath.2013.01165.

    Article  PubMed  Google Scholar 

  55. Radović N, Turner R, Bacalja J. Primary “Pure” Large Cell Neuroendocrine Carcinoma of the Urinary Bladder: A Case Report and Review of the Literature. Clinical Genitourinary Cancer. 2015;13(5):e375–e377. https://doi.org/10.1016/j.clgc.2015.03.005.

  56. Colarossi C, Pino P, Giuffrida D, et al. Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report. Diagn Pathol. 2013;8:19. https://doi.org/10.1186/1746-1596-8-19.

  57. Liu C, Mo C-Q, Jiang S-J, Pan J-C, Qiu S-P, Wang D-H. Primary paraganglioma of seminal vesicle. Chin Med J. 2016;129(13):1627–8. https://doi.org/10.4103/0366-6999.184471.

    Article  PubMed  Google Scholar 

  58. Liu H-W, Liu L-R, Cao D-H, Wei Q. Paraganglioma in the renal pelvis. Kaohsiung J Med Sci. 2014;30(6):319–20. https://doi.org/10.1016/j.kjms.2013.04.007.

    Article  PubMed  Google Scholar 

  59. Awasthi NP, Kumari N, Krishnani N, Goel A. “Functional” paraganglioma of ureter: an unusual case. Indian J Pathol Microbiol. 2011;54(2):405–6. https://doi.org/10.4103/0377-4929.81631.

    Article  PubMed  Google Scholar 

  60. Alataki D, Triantafyllidis A, Gaal J, et al. A non-catecholamine-producing sympathetic paraganglioma of the spermatic cord: the importance of performing candidate gene mutation analysis. Virchows Arch. 2010;457(5):619–22. https://doi.org/10.1007/s00428-010-0966-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Yi C, Han L, Yang R, Yu J. Paraganglioma of the renal pelvis: a case report and review of literature. Tumori. 2017;103(Suppl. 1):e47–9. https://doi.org/10.5301/tj.5000677.

    Article  PubMed  Google Scholar 

  62. Kwon A-Y, Kang H, An HJ, et al. Spermatic cord paraganglioma with histologically malignant features. Urology. 2016;93:e7–8. https://doi.org/10.1016/j.urology.2016.03.014.

    Article  PubMed  Google Scholar 

  63. Alvarenga CA, Lopes JM, Vinagre J, et al. Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. Sao Paulo Med J. 2012;130(1):57–60.

    Article  Google Scholar 

  64. Alberti C. Urology pertinent neuroendocrine tumors: focusing on renal pelvis, bladder, prostate located sympathetic functional paragangliomas. G Chir. 2016;37(2):55–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Cheng L, Leibovich BC, Cheville JC, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer. 2000;88(4):844–52. https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<844::aid-cncr15>3.0.co;2-i.

    Article  CAS  PubMed  Google Scholar 

  66. Adraktas D, Caserta M, Tchelepi H. Paraganglioma of the urinary bladder. Ultrasound Q. 2014;30(3):233–5. https://doi.org/10.1097/RUQ.0000000000000113.

    Article  PubMed  Google Scholar 

  67. Liang J, Li H, Gao L, Yin L, Yin L, Zhang J. Bladder paraganglioma: clinicopathology and magnetic resonance imaging study of five patients. Urol J. 2016;13(2):2605–11.

    PubMed  Google Scholar 

  68. Feng N, Li X, Gao H-D, Liu Z-L, Shi L-J, Liu W-Z. Urinary bladder malignant paraganglioma with vertebral metastasis: a case report with literature review. Chin J Cancer. 2013;32(11):624–8. https://doi.org/10.5732/cjc.012.10317.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Pichler R, Heidegger I, Klinglmair G, et al. Unrecognized paraganglioma of the urinary bladder as a cause for basilar-type migraine. Urol Int. 2014;92(4):482–7. https://doi.org/10.1159/000348829.

    Article  PubMed  Google Scholar 

  70. Hanji AM, Rohan VS, Patel JJ, Tankshali RA. Pheochromocytoma of the urinary bladder: a rare cause of severe hypertension. Saudi J Kidney Dis Transpl. 2012;23(4):813–6. https://doi.org/10.4103/1319-2442.98167.

    Article  PubMed  Google Scholar 

  71. Bagchi A, Dushaj K, Shrestha A, et al. Urinary bladder paraganglioma presenting as micturition-induced palpitations, dyspnea, and angina. Am J Case Rep. 2015;16:283–6. https://doi.org/10.12659/AJCR.891388.

    Article  PubMed  PubMed Central  Google Scholar 

  72. She HL, Chan PH, Cheung SCW. Urinary bladder paraganglioma in a post-heart transplant patient. Ann Acad Med Singap. 2012;41(8):362–3.

    PubMed  Google Scholar 

  73. Martucci VL, Lorenzo ZG, Weintraub M, et al. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015;33(4):167.e13–20. https://doi.org/10.1016/j.urolonc.2014.11.017.

    Article  CAS  Google Scholar 

  74. Ranaweera M, Chung E. Bladder paraganglioma: A report of case series and critical review of current literature. World J Clinic Cases. 2014;2(10):591. https://doi.org/10.12998/wjcc.v2.i10.591.

    Article  Google Scholar 

  75. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(12):e68–75. https://doi.org/10.1158/1078-0432.CCR-17-0547.

    Article  CAS  PubMed  Google Scholar 

  76. Raygada M, Pasini B, Stratakis CA. Hereditary paragangliomas. Adv Otorhinolaryngol. 2011;70:99–106. https://doi.org/10.1159/000322484.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Wang H, Ye H, Guo A, et al. Bladder paraganglioma in adults: MR appearance in four patients. Eur J Radiol. 2011;80(3):e217–20. https://doi.org/10.1016/j.ejrad.2010.09.020.

    Article  PubMed  Google Scholar 

  78. Bosserman AJ, Dai D, Lu Y. Imaging characteristics of a bladder wall paraganglioma. Clin Nucl Med. 2019;44(1):66–7. https://doi.org/10.1097/RLU.0000000000002324.

    Article  PubMed  Google Scholar 

  79. Bishnoi K, Bora GS, Mavuduru RS, Devana SK, Singh SK, Mandal AK. Bladder paraganglioma: safe and feasible management with robot assisted surgery. J Robot Surg. 2016;10(3):275–8. https://doi.org/10.1007/s11701-016-0573-0.

    Article  CAS  PubMed  Google Scholar 

  80. Stigliano A, Lardo P, Cerquetti L, et al. Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: a case report. Medicine (Baltimore). 2018;97(30):e10904. https://doi.org/10.1097/MD.0000000000010904.

    Article  Google Scholar 

  81. Nayyar R, Singh P, Gupta NP. Robotic management of pheochromocytoma of the vesicoureteric junction. JSLS. 2010;14(2):309–12. https://doi.org/10.4293/108680810X12785289145042.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Park S, Kang SY, Kwon GY, et al. Clinicopathologic characteristics and mutational status of succinate dehydrogenase genes in paraganglioma of the urinary bladder: a multi-institutional Korean study. Arch Pathol Lab Med. 2017;141(5):671–7. https://doi.org/10.5858/arpa.2016-0403-OA.

    Article  CAS  PubMed  Google Scholar 

  83. Papathomas TG, de Krijger RR, Tischler AS. Paragangliomas: update on differential diagnostic considerations, composite tumors, and recent genetic developments. Semin Diagn Pathol. 2013;30(3):207–23. https://doi.org/10.1053/j.semdp.2013.06.006.

    Article  PubMed  Google Scholar 

  84. Maeda M, Funahashi Y, Katoh M, Fujita T, Tsuruta K, Gotoh M. Malignant bladder pheochromocytoma with SDHB genetic mutation. Aktuelle Urol. 2013;44(5):381–2. https://doi.org/10.1055/s-0033-1345147.

    Article  CAS  PubMed  Google Scholar 

  85. Beilan J, Lawton A, Hajdenberg J, Rosser CJ. Locally advanced paraganglioma of the urinary bladder: a case report. BMC Res Notes. 2013;6:156. https://doi.org/10.1186/1756-0500-6-156.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Iwamoto G, Kawahara T, Tanabe M, et al. Paraganglioma in the bladder: a case report. J Med Case Rep. 2017;11(1):306. https://doi.org/10.1186/s13256-017-1473-2.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Menon S, Goyal P, Suryawanshi P, et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol. 2014;57(1):19–23. https://doi.org/10.4103/0377-4929.130873.

    Article  PubMed  Google Scholar 

  88. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13–22. https://doi.org/10.1097/PAS.0b013e3182a0218f.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Nonaka D, Wang BY, Edmondson D, Beckett E, Sun C-CJ. A study of gata3 and phox2b expression in tumors of the autonomic nervous system. Am J Surg Pathol. 2013;37(8):1236–41. https://doi.org/10.1097/PAS.0b013e318289c765.

    Article  PubMed  Google Scholar 

  90. So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol. 2013;26(10):1365–70. https://doi.org/10.1038/modpathol.2013.76.

    Article  CAS  PubMed  Google Scholar 

  91. Ghafoor A-U-R, Yousaf I, Pervez R, Khan RU, Mir K. Paraganglioma of urinary bladder: an unusual presentation. Pitfalls in diagnosis and treatment. J Pak Med Assoc. 2012;62(1):63–5.

    PubMed  Google Scholar 

  92. Grignon DJ, Ro JY, Mackay B, et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol. 1991;22(11):1162–9.

    Article  CAS  Google Scholar 

  93. Ranaweera M, Chung E. Bladder paraganglioma: a report of case series and critical review of current literature. World J Clin Cases. 2014;2(10):591–5. https://doi.org/10.12998/wjcc.v2.i10.591.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Ahmed N. Shehabeldin

  2. Department of Pathology and Genomic Medicine, Weill Medical College of Cornell University/Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Authors
  1. Ahmed N. Shehabeldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Y. Ro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Y. Ro .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Haijun Zhou

  2. Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shehabeldin, A.N., Ro, J.Y. (2021). Neuroendocrine Tumors of the Urinary Bladder. In: Zhou, H., Guo, C.C., Ro, J.Y. (eds) Urinary Bladder Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-71509-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71509-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71508-3

  • Online ISBN: 978-3-030-71509-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation